Humana Inc. (NYSE:HUM) Holdings Raised by Franklin Resources Inc.

Franklin Resources Inc. grew its stake in shares of Humana Inc. (NYSE:HUM) by 0.6% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 941,885 shares of the insurance provider’s stock after acquiring an additional 5,814 shares during the period. Franklin Resources Inc. owned 0.78% of Humana worth $238,966,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. FPC Investment Advisory Inc. purchased a new position in Humana in the fourth quarter valued at about $27,000. Centricity Wealth Management LLC acquired a new stake in shares of Humana during the 4th quarter valued at about $30,000. LFA Lugano Financial Advisors SA grew its stake in shares of Humana by 56.3% in the 4th quarter. LFA Lugano Financial Advisors SA now owns 125 shares of the insurance provider’s stock valued at $32,000 after buying an additional 45 shares in the last quarter. OFI Invest Asset Management acquired a new position in Humana in the fourth quarter worth approximately $33,000. Finally, Atwood & Palmer Inc. raised its position in Humana by 64.5% during the fourth quarter. Atwood & Palmer Inc. now owns 153 shares of the insurance provider’s stock valued at $39,000 after acquiring an additional 60 shares in the last quarter. 92.38% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages have recently commented on HUM. Cantor Fitzgerald restated a “neutral” rating and set a $290.00 price target on shares of Humana in a research note on Wednesday, February 12th. Barclays increased their target price on shares of Humana from $255.00 to $270.00 and gave the stock an “equal weight” rating in a research report on Thursday, February 13th. Truist Financial upped their price target on Humana from $260.00 to $290.00 and gave the stock a “hold” rating in a research note on Monday, January 6th. StockNews.com downgraded Humana from a “buy” rating to a “hold” rating in a research note on Tuesday, March 18th. Finally, JPMorgan Chase & Co. reduced their target price on Humana from $257.00 to $256.00 and set a “neutral” rating for the company in a report on Tuesday, February 18th. Eighteen research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat, Humana has a consensus rating of “Hold” and a consensus price target of $285.68.

Humana Trading Down 0.0 %

Shares of HUM opened at $264.55 on Wednesday. The stock’s 50-day moving average price is $269.37 and its 200 day moving average price is $272.67. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.68. The firm has a market capitalization of $31.93 billion, a price-to-earnings ratio of 26.59, a P/E/G ratio of 2.05 and a beta of 0.57. Humana Inc. has a 12-month low of $213.31 and a 12-month high of $406.46.

Humana (NYSE:HUM) last released its quarterly earnings data on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. As a group, research analysts predict that Humana Inc. will post 16.47 earnings per share for the current year.

Humana Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, April 25th. Investors of record on Friday, March 28th will be given a $0.885 dividend. This represents a $3.54 annualized dividend and a yield of 1.34%. The ex-dividend date of this dividend is Friday, March 28th. Humana’s dividend payout ratio (DPR) is presently 35.58%.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.